Pentoxifylline plus CoQ10 versus CoQ10 alone to improve sperm motility in men with asthenozoospermia
Effect of Pentoxifylline Plus Coenzyme Q10 Combination Therapy Compared to Coenzyme Q10 Alone on Sperm Motility in Sub-fertile Male With Asthenozoospermia
This trial will test whether adding pentoxifylline to CoQ10 improves sperm movement in subfertile men with low sperm motility.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 56 (estimated) |
| Ages | 20 Years to 50 Years |
| Sex | Male |
| Sponsor | Bangladesh Medical University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Dhaka, Shahbag) |
| Trial ID | NCT07252518 on ClinicalTrials.gov |
What this trial studies
This is a randomized, controlled trial enrolling 56 subfertile men with asthenozoospermia at Bangladesh Medical University. Participants are randomly assigned to receive pentoxifylline 400 mg twice daily plus CoQ10 100 mg twice daily, or CoQ10 100 mg twice daily alone, for three months. Baseline semen analysis requires two samples and the main outcome is change in sperm motility after three months, with monitoring for adverse events. Allocation is concealed using serially numbered opaque envelopes and safety and demographic data are collected throughout.
Who should consider this trial
Good fit: Subfertile men aged 20–50 with confirmed asthenozoospermia (total motility 20% to <42%) who meet the listed inclusion and exclusion criteria are eligible.
Not a fit: Men with severe oligoasthenoteratozoospermia, recent antioxidant use, certain medical/endocrine/genetic disorders, prior chemo/radiotherapy, genital infection or surgery, substance abuse, or hypersensitivity to xanthine products are excluded and unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the combination could improve sperm motility and may increase the chances of conception for affected men.
How similar studies have performed: Previous studies report modest improvements in sperm parameters with CoQ10 or pentoxifylline individually, but randomized data on their combined use are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Sub fertile men with asthenozoospermia(Total motility20% to less than 42%) according to WHO semen analysis,2021. * Age 20-50 years. Exclusion Criteria: * Severe oligoasthenoteratozoospermia * Any medical, endocrine and genetic disorders, history of chemotherapy or radiotherapy, genital infection, genital surgery. * Antioxidants supplmentation in the last 3 months * Drug, alcohol or substance abuse, psycho-sexual abnormalities. * Any known hypersensitivity to xanthine related product, recent cerebral or retinal haemorrhage Severe oligoasthenoteratozoospermia * Any medical, endocrine and genetic disorders, history of chemotherapy or radiotherapy, genital infection, genital surgery. * Antioxidants supplmentation in the last 3 months * Drug, alcohol or substance abuse, psycho-sexual abnormalities. * Any known hypersensitivity to xanthine related product, recent cerebral or retinal haemorrhage
Where this trial is running
Dhaka, Shahbag
- Bangladesh Medical University — Dhaka, Shahbag, Bangladesh (Recruiting)
Study contacts
- Principal investigator: Jesmine Banu, MS — Bangladesh Medical University
- Study coordinator: Mst.Sumyara Khatun, MS
- Email: sumirmc09@gmail.com
- Phone: +8801746046581
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.